慢性腎臓病の世界市場レポート 2025年

慢性腎臓病市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.3％で958億5,000万米ドルに成長します。予測期間の成長は、ヘルスケア政策の重視、精密医療の開発、肥満率の上昇、慢性疾患の増加、医療アクセスの改善などに起因すると考えられます。予測期間の主な動向には、早期スクリーニングキャンペーン、遠隔医療と遠隔モニタリング、患者エンパワーメントプログラム、地域密着型ケアイニシアチブ、栄養療法統合などがあります。

腎臓病の有病率の上昇は、慢性腎臓病（CKD）市場の拡大を促進します。腎臓病は、腎臓の機能や構造に影響を及ぼす様々な疾患を包含しており、多くの場合、症状の管理、血圧のコントロール、タンパク質の損失を最小限に抑えるための薬物療法が必要となります。2022年7月の米国疾病予防管理センター（Centers for Disease Control and Prevention）のデータによると、米国では約15％、3,700万人が腎臓病と闘っており、その有病率が急上昇していることが明らかになっています。その結果、この有病率の高まりが慢性腎臓病市場の成長軌道を推進する重要な要因となっています。

高齢化人口の急増は、慢性腎臓病市場の拡大に大きく貢献すると予測されています。高齢化」という用語は、社会や人口における高齢者の割合が高くなることを特徴とする人口動態を示します。この人口動態の変化は、高齢者における腎臓関連の問題の発生率の上昇により、慢性腎臓病（CKD）管理への依存度が高まることと密接に関連しています。加齢に伴い、CKDを含む腎臓疾患のリスクは高まる傾向にあります。特に、世界保健機関（WHO）が2022年10月に発表した報告書では、60歳以上の世界人口の急速な増加が予測されており、2050年までに倍増し、21億人に達すると推定されています。したがって、高齢化人口の増加は、慢性腎臓病市場の成長軌道を推進する重要な要因となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界慢性腎臓病 PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の慢性腎臓病市場：成長率分析
• 世界の慢性腎臓病市場の実績：規模と成長, 2019-2024
• 世界の慢性腎臓病市場の予測：規模と成長, 2024-2029, 2034F
• 世界慢性腎臓病総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の慢性腎臓病市場診断による、実績と予測, 2019-2024, 2024-2029F, 2034F
• 血液検査
• 尿検査
• 画像検査
• 腎臓生検
• 世界の慢性腎臓病市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 薬物
• 透析
• 腎臓移植
• ACE阻害薬
• 血液検査
• その他の治療法
• 世界の慢性腎臓病市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 静脈内
• 皮下
• 世界の慢性腎臓病市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院と診療所
• 外来手術センター（ASC）
• 透析センター
• その他のエンドユーザー
• 世界の慢性腎臓病市場、血液検査の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 血清クレアチニン検査
• 糸球体濾過率（GFR）検査
• 血中尿素窒素（BUN）検査
• 電解質検査
• 世界の慢性腎臓病市場尿検査の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 尿検査
• 24時間尿採取
• 尿タンパク質検査
• 尿アルブミン・クレアチニン比（ACR）
• 世界の慢性腎臓病市場、画像検査のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 超音波
• CTスキャン
• MRI
• X線
• 世界の慢性腎臓病市場、腎生検のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経皮腎生検
• 開腹腎生検
• 腹腔鏡下腎生検

第7章 地域別・国別分析

• 世界の慢性腎臓病市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の慢性腎臓病市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 慢性腎臓病市場：競合情勢
• 慢性腎臓病市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson and Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis International AG
• Sanofi SA
• Bristol-Myers Squibb Company
• Abbott Laboratories Inc.
• GlaxoSmithKline PLC
• Takeda Pharmaceuticals Ltd.
• Eli Lilly and Company
• Boehringer Ingelheim International GmbH
• Amgen Inc.
• Novo Nordisk AS
• Siemens Healthineers AG
• AstraZeneca Pharmaceuticals LP
• Teva Pharmaceutical Industries Ltd.
• Beckman Coulter Inc.
• Kissei Pharmaceutical Co. Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 慢性腎臓病市場2029：新たな機会を提供する国
• 慢性腎臓病市場2029：新たな機会を提供するセグメント
• 慢性腎臓病市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Chronic kidney disease is characterized by impaired kidney function, leading to the inefficient filtration of blood, resulting in the accumulation of excess fluid and waste in the body. Common causes include diabetes, high blood pressure, and obesity. Managing this condition requires ongoing care and may progress to end-stage renal failure, necessitating dialysis or transplantation.

Key diagnostic tests for chronic kidney disease include blood tests, urine tests, imaging tests, and kidney biopsy. Blood tests involve the examination of a blood sample for medical evaluation. Treatment modalities encompass drugs, dialysis, kidney transplants, ACE inhibitors, and other interventions. These drugs can be administered through oral, intravenous, and subcutaneous routes, catering to various end-users such as hospitals, clinics, ambulatory surgery centers (ASCS), dialysis centers, and others.

The chronic kidney disease market research report is one of a series of new reports from The Business Research Company that provides chronic kidney disease market statistics, including the chronic kidney disease industry global market size, regional shares, competitors with a chronic kidney disease market share, detailed chronic kidney disease market segments, market trends, and opportunities, and any further data you may need to thrive in the chronic kidney disease industry. This chronic kidney disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The chronic kidney disease market size has grown strongly in recent years. It will grow from $70.65 billion in 2024 to $75.09 billion in 2025 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to hypertension and diabetes epidemic, aging population, unhealthy lifestyles, healthcare access disparities, medical advances

The chronic kidney disease market size is expected to see strong growth in the next few years. It will grow to $95.85 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to healthcare policy focus, precision medicine development, rise in obesity rates, growth in chronic diseases, improved healthcare access. Major trends in the forecast period include early screening campaigns, telemedicine and remote monitoring, patient empowerment programs, community-based care initiatives, nutritional therapy integration.

The escalating prevalence of kidney disease is poised to drive the expansion of the chronic kidney disease (CKD) market. Kidney diseases encompass various conditions that affect the kidneys' function and structure, often necessitating medication to manage symptoms, control blood pressure, and minimize protein loss. As per data from the Centers for Disease Control and Prevention in July 2022, approximately 15% or 37 million individuals in the US grapple with kidney disease, underscoring the surge in its prevalence. Consequently, this mounting prevalence is a key driver propelling the growth trajectory of the chronic kidney disease market.

The burgeoning aging population is anticipated to contribute significantly to the chronic kidney disease market's expansion. The term 'aging population' denotes a demographic trend marked by a higher proportion of elderly individuals within a society or populace. This demographic shift is closely associated with an elevated reliance on chronic kidney disease (CKD) management due to the rising incidence of kidney-related issues among the elderly. With age, the risk of kidney ailments, including CKD, tends to escalate. Notably, the World Health Organization's October 2022 report highlights a rapid growth projection for the global population aged 60 years and older, expected to double by 2050, reaching an estimated 2.1 billion individuals. Hence, the increasing aging demographic is a significant factor propelling the chronic kidney disease market's growth trajectory.

Product innovation stands out as a pivotal trend gaining momentum in the chronic kidney disease market. Companies navigating this sector are dedicating efforts toward developing innovative products to fortify their market presence. For example, Bayer, a Germany-based biotechnology and pharmaceutical entity, unveiled Kerendia (finerenone) in August 2022. This groundbreaking medicine, categorized as a non-steroidal, selective mineralocorticoid receptor antagonist, offers a novel approach to decelerate chronic kidney disease progression among diabetic patients. Its distinctive mechanism involves the blocking of mineralocorticoid receptor (MR) overactivation, thereby addressing factors contributing to CKD progression and associated cardiovascular damage, setting it apart from existing treatments.

Major players in the chronic kidney disease market are engaging in strategic partnerships to explore the safety and efficacy of an enhanced Automated Wearable Artificial Kidney Peritoneal Dialysis (AWAK PD) device. These strategic partnerships involve collaborations where companies harness each other's strengths and resources to achieve mutual benefits. As an illustration, in June 2023, AWAK Technologies Pte Ltd., a Singapore-based medical technology firm, forged a partnership with Singapore General Hospital Pte Ltd. (SGH), an academic health science center and hospital entity in Singapore. This collaboration aims to revolutionize kidney disease diagnosis, treatment, and management by spearheading the development and evaluation of AWAK PD, a wearable and ultra-portable peritoneal dialysis (PD) system. This innovative system allows end-stage kidney disease patients the flexibility to undergo dialysis at home and while on the move, thereby enhancing their quality of life and treatment convenience.

In January 2023, the US-based biopharmaceutical company AstraZeneca Pharmaceuticals LP successfully acquired CinCor Pharma Inc. for $1.8 billion. Through this acquisition, AstraZeneca aims to enrich its cardiorenal pipeline by incorporating CinCor's candidate medicine, baxdrostat (CIN-107). Baxdrostat is an aldosterone synthase inhibitor (ASI) designed for blood pressure control in the treatment of resistant hypertension. CinCor Pharma Inc., based in the US, is a clinical-stage biopharmaceutical company specializing in the development of products for the treatment of resistant and uncontrolled hypertension, as well as chronic kidney disease.

Major companies operating in the chronic kidney disease market include Pfizer Inc, Johnson and Johnson Services Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis International AG, Sanofi SA, Bristol-Myers Squibb Company, Abbott laboratories Inc., GlaxoSmithKline PLC, Takeda Pharmaceuticals Ltd., Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Novo Nordisk AS, Siemens Healthineers AG, AstraZeneca Pharmaceuticals LP, Teva Pharmaceutical Industries Ltd., Beckman Coulter Inc., Kissei Pharmaceutical Co. Ltd., Akebia Therapeutics Inc., Mission Therapeutics Ltd., Tricida Inc., Regulus Therapeutics Inc., Goldfinch Bio Co, Alio Inc., Monogram Health, Strive Health, Maze Therapeutics, ProKidney Corp

North America was the largest region in the chronic kidney disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic kidney disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the chronic kidney disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chronic kidney disease market consists of revenues earned by entities by providing peritoneal dialysis, in-center hemodialysis, and home hemodialysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic kidney disease market also includes sales such as captopril, enalapril, finerenone, and fosinopril used during the treatment procedure. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chronic Kidney Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chronic kidney disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for chronic kidney disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The chronic kidney disease market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Diagnosis: Blood Test; Urine Test; Imaging Test; Kidney Biopsy
• 2) By Treatment: Drugs; Dialysis; Kidney Transplant; ACE Inhibitors; Blood Test; Other Treatments
• 3) By Route of Administration: Oral; Intravenous; Subcutaneous
• 4) By End-User: Hospital And Clinics; Ambulatory Surgery Centers (ASCs); Dialysis Centers; Other End-Users
• Subsegments:
• 1) By Blood Test: Serum Creatinine Test; Glomerular Filtration Rate (GFR) Test; Blood Urea Nitrogen (BUN) Test; Electrolyte Tests
• 2) By Urine Test: Urinalysis; 24-hour Urine Collection; Urine Protein Test; Urine Albumin-To-Creatinine Ratio (ACR)
• 3) By Imaging Test: Ultrasound; CT Scan; MRI; X-ray
• 4) By Kidney Biopsy: Percutaneous Kidney Biopsy; Open Kidney Biopsy; Laparoscopic Kidney Biopsy
• Companies Mentioned: Pfizer Inc; Johnson and Johnson Services Inc.; F. Hoffmann-La Roche Ltd.; AbbVie Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Chronic Kidney Disease Market Characteristics

3. Chronic Kidney Disease Market Trends And Strategies

4. Chronic Kidney Disease Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Chronic Kidney Disease Growth Analysis And Strategic Analysis Framework

• 5.1. Global Chronic Kidney Disease PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Chronic Kidney Disease Market Growth Rate Analysis
• 5.4. Global Chronic Kidney Disease Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Chronic Kidney Disease Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Chronic Kidney Disease Total Addressable Market (TAM)

6. Chronic Kidney Disease Market Segmentation

• 6.1. Global Chronic Kidney Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Blood Test
• Urine Test
• Imaging Test
• Kidney Biopsy
• 6.2. Global Chronic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Drugs
• Dialysis
• Kidney Transplant
• ACE Inhibitors
• Blood Test
• Other Treatments
• 6.3. Global Chronic Kidney Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravenous
• Subcutaneous
• 6.4. Global Chronic Kidney Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital and Clinics
• Ambulatory Surgery Centers (ASCs)
• Dialysis Centers
• Other End-Users
• 6.5. Global Chronic Kidney Disease Market, Sub-Segmentation Of Blood Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Serum Creatinine Test
• Glomerular Filtration Rate (GFR) Test
• Blood Urea Nitrogen (BUN) Test
• Electrolyte Tests
• 6.6. Global Chronic Kidney Disease Market, Sub-Segmentation Of Urine Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Urinalysis
• 24-hour Urine Collection
• Urine Protein Test
• Urine Albumin-To-Creatinine Ratio (ACR)
• 6.7. Global Chronic Kidney Disease Market, Sub-Segmentation Of Imaging Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ultrasound
• CT Scan
• MRI
• X-ray
• 6.8. Global Chronic Kidney Disease Market, Sub-Segmentation Of Kidney Biopsy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Percutaneous Kidney Biopsy
• Open Kidney Biopsy
• Laparoscopic Kidney Biopsy

7. Chronic Kidney Disease Market Regional And Country Analysis

• 7.1. Global Chronic Kidney Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Chronic Kidney Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Chronic Kidney Disease Market

• 8.1. Asia-Pacific Chronic Kidney Disease Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Chronic Kidney Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Chronic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Chronic Kidney Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Chronic Kidney Disease Market

• 9.1. China Chronic Kidney Disease Market Overview
• 9.2. China Chronic Kidney Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Chronic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Chronic Kidney Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Chronic Kidney Disease Market

• 10.1. India Chronic Kidney Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Chronic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Chronic Kidney Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Chronic Kidney Disease Market

• 11.1. Japan Chronic Kidney Disease Market Overview
• 11.2. Japan Chronic Kidney Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Chronic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Chronic Kidney Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Chronic Kidney Disease Market

• 12.1. Australia Chronic Kidney Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Chronic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Chronic Kidney Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Chronic Kidney Disease Market

• 13.1. Indonesia Chronic Kidney Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Chronic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Chronic Kidney Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Chronic Kidney Disease Market

• 14.1. South Korea Chronic Kidney Disease Market Overview
• 14.2. South Korea Chronic Kidney Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Chronic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Chronic Kidney Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Chronic Kidney Disease Market

• 15.1. Western Europe Chronic Kidney Disease Market Overview
• 15.2. Western Europe Chronic Kidney Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Chronic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Chronic Kidney Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Chronic Kidney Disease Market

• 16.1. UK Chronic Kidney Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Chronic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Chronic Kidney Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Chronic Kidney Disease Market

• 17.1. Germany Chronic Kidney Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Chronic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Chronic Kidney Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Chronic Kidney Disease Market

• 18.1. France Chronic Kidney Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Chronic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Chronic Kidney Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Chronic Kidney Disease Market

• 19.1. Italy Chronic Kidney Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Chronic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Chronic Kidney Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Chronic Kidney Disease Market

• 20.1. Spain Chronic Kidney Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Chronic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Chronic Kidney Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Chronic Kidney Disease Market

• 21.1. Eastern Europe Chronic Kidney Disease Market Overview
• 21.2. Eastern Europe Chronic Kidney Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Chronic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Chronic Kidney Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Chronic Kidney Disease Market

• 22.1. Russia Chronic Kidney Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Chronic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Chronic Kidney Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Chronic Kidney Disease Market

• 23.1. North America Chronic Kidney Disease Market Overview
• 23.2. North America Chronic Kidney Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Chronic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Chronic Kidney Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Chronic Kidney Disease Market

• 24.1. USA Chronic Kidney Disease Market Overview
• 24.2. USA Chronic Kidney Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Chronic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Chronic Kidney Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Chronic Kidney Disease Market

• 25.1. Canada Chronic Kidney Disease Market Overview
• 25.2. Canada Chronic Kidney Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Chronic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Chronic Kidney Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Chronic Kidney Disease Market

• 26.1. South America Chronic Kidney Disease Market Overview
• 26.2. South America Chronic Kidney Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Chronic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Chronic Kidney Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Chronic Kidney Disease Market

• 27.1. Brazil Chronic Kidney Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Chronic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Chronic Kidney Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Chronic Kidney Disease Market

• 28.1. Middle East Chronic Kidney Disease Market Overview
• 28.2. Middle East Chronic Kidney Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Chronic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Chronic Kidney Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Chronic Kidney Disease Market

• 29.1. Africa Chronic Kidney Disease Market Overview
• 29.2. Africa Chronic Kidney Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Chronic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Chronic Kidney Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Chronic Kidney Disease Market Competitive Landscape And Company Profiles

• 30.1. Chronic Kidney Disease Market Competitive Landscape
• 30.2. Chronic Kidney Disease Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson and Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Chronic Kidney Disease Market Other Major And Innovative Companies

• 31.1. Novartis International AG
• 31.2. Sanofi SA
• 31.3. Bristol-Myers Squibb Company
• 31.4. Abbott Laboratories Inc.
• 31.5. GlaxoSmithKline PLC
• 31.6. Takeda Pharmaceuticals Ltd.
• 31.7. Eli Lilly and Company
• 31.8. Boehringer Ingelheim International GmbH
• 31.9. Amgen Inc.
• 31.10. Novo Nordisk AS
• 31.11. Siemens Healthineers AG
• 31.12. AstraZeneca Pharmaceuticals LP
• 31.13. Teva Pharmaceutical Industries Ltd.
• 31.14. Beckman Coulter Inc.
• 31.15. Kissei Pharmaceutical Co. Ltd.

32. Global Chronic Kidney Disease Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Chronic Kidney Disease Market

34. Recent Developments In The Chronic Kidney Disease Market

35. Chronic Kidney Disease Market High Potential Countries, Segments and Strategies

• 35.1 Chronic Kidney Disease Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Chronic Kidney Disease Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Chronic Kidney Disease Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer